Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V, Jensen B, Feldt T, Fischer JC, Bode JG, Matuschek C, Bölke E, Budach W, Plettenberg C, Scheckenbach K, Kindgen-Milles D, Timm J, Müller L, Kolbe H, Stöhr A, Calles C, Hippe A, Verde P, Spinner CD, Schneider J, Wolf T, Kern WV, Nattermann J, Zoufaly A, Ohmann C, Luedde T; RES-Q-HR Trial Team.
Keitel V, et al. Among authors: kern wv.
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
Trials. 2021.
PMID: 34001215
Free PMC article.